We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cathay International Holdings Ld | LSE:CTI | London | Ordinary Share | BMG1965E1030 | COM SHS $0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.75 | 0.50 | 1.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCTI
RNS Number : 6011Z
Cathay International Holdings Ld
16 March 2017
Cathay International Holdings Limited
("Cathay" or the "Company")
Notice of Annual Results 2016
Hong Kong, 16 March 2017 - Cathay International Holdings Limited (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces the Company will issue its Annual Results for the year ended 31 December 2016 on Thursday, 30 March 2017.
-Ends-
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Tel: +852 2828 9289 Patrick Sung (Director and Controller) N+1 Singer Aubrey Powell / Lauren Kettle - Corporate Tel: +44 (0) 20 7496 Finance 3000 Brough Ransom - Sales Consilium Strategic Communications Limited Mary-Jane Elliott / Matthew Neal / Tel: +44 (0) 203709 Lindsey Neville 5708
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBLGDXUDBBGRU
(END) Dow Jones Newswires
March 16, 2017 03:01 ET (07:01 GMT)
1 Year Cathay International Hol... Chart |
1 Month Cathay International Hol... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions